Marcum Wealth LLC Has $473,000 Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Marcum Wealth LLC reduced its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 6.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 9,379 shares of the biotechnology company’s stock after selling 621 shares during the period. Marcum Wealth LLC’s holdings in Corcept Therapeutics were worth $473,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CORT. Capital Performance Advisors LLP acquired a new stake in shares of Corcept Therapeutics during the third quarter worth approximately $25,000. Kathleen S. Wright Associates Inc. bought a new stake in Corcept Therapeutics during the 3rd quarter worth approximately $36,000. GAMMA Investing LLC increased its holdings in Corcept Therapeutics by 85.4% during the 3rd quarter. GAMMA Investing LLC now owns 2,490 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 1,147 shares in the last quarter. KBC Group NV raised its position in Corcept Therapeutics by 21.3% in the 3rd quarter. KBC Group NV now owns 2,822 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 496 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in Corcept Therapeutics in the second quarter worth $205,000. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CORT has been the subject of a number of research analyst reports. StockNews.com cut Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, November 25th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Corcept Therapeutics in a research note on Thursday, October 31st. Truist Financial increased their price target on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the company a “buy” rating in a research note on Monday, September 30th. Piper Sandler boosted their price objective on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 18th. Finally, Sandler O’Neill reiterated a “buy” rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Corcept Therapeutics currently has a consensus rating of “Buy” and an average target price of $65.25.

Corcept Therapeutics Stock Up 1.2 %

Shares of NASDAQ CORT opened at $51.66 on Wednesday. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $5.41 billion, a PE ratio of 41.00 and a beta of 0.56. The firm’s 50-day moving average is $54.90 and its 200-day moving average is $44.47. Corcept Therapeutics Incorporated has a 1 year low of $20.84 and a 1 year high of $62.22.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.14. The firm had revenue of $182.55 million for the quarter, compared to analysts’ expectations of $171.97 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The business’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same period last year, the firm earned $0.28 earnings per share. Equities analysts expect that Corcept Therapeutics Incorporated will post 1.35 EPS for the current year.

Insider Activity at Corcept Therapeutics

In other Corcept Therapeutics news, insider Sean Maduck sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total value of $1,007,800.00. Following the completion of the sale, the insider now owns 85,318 shares of the company’s stock, valued at approximately $4,299,174.02. This represents a 18.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.88, for a total transaction of $131,736.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,011 shares of company stock worth $1,951,268. 20.50% of the stock is owned by insiders.

Corcept Therapeutics Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.